

Targeting systemic inflammation to improve endothelial function in obesity

Submission date 10/06/2011	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 10/06/2011	Overall study status Completed	☐ Protocol
Last Edited 19/05/2022	Condition category Nutritional, Metabolic, Endocrine	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Stephen B Wheatcroft

Contact details
The Light Laboratories
University of Leeds
Clarendon Way
Leeds
United Kingdom
LS2 9DA
+44 113 343 7760
s.b.wheatcroft@leeds.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
2009-016855-23

Protocol serial number
9379

Study information

Scientific Title

Targeting systemic inflammation to improve endothelial function in obesity

Study objectives

The aim of this study is to investigate the effect of reducing inflammation with pentoxifylline on vascular endothelial function in individuals with obesity

Ethics approval required

Old ethics approval format

Ethics approval(s)

02/02/2010, ref: 10/H1005/5

Primary study design

Interventional

Study design

Randomised; Interventional; Design type: Not specified, Treatment

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Interventions

A total of 50 participants with obesity will be randomised to receive pentoxifylline 400mg tablets or an inactive control preparation three times daily for eight weeks.

Follow Up Length: 2 month(s); Study Entry : Single Randomisation only

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Pentoxifylline

Primary outcome(s)

Flow mediated dilatation of brachial artery (%); Timepoint(s): at end of treatment period

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/02/2012

Eligibility

Key inclusion criteria

1. Age 18-65
 2. Obesity (Body Mass Index 30 or greater)
 3. Not taking other medication (apart from oral contraceptives)
- Target Gender: Male & Female; Upper Age Limit 65 years ; Lower Age Limit 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

65 Years

Sex

All

Key exclusion criteria

1. Diabetes
2. Hypertension
3. Hyperlipidaemia
4. Cardiovascular disease or history of cardiac arrhythmias
5. Chronic inflammatory disorders (e.g. rheumatoid arthritis, connective tissue disorders, gout, inflammatory bowel disease, chronic infections)
6. Acute inflammatory illnesses (e.g. upper respiratory tract infections)
7. Allergy to pentoxifylline or other methyl xanthine drugs or concomitant use of sildenafil, tadalafil, vardenafil or other phosphodiesterase inhibitors
8. History of cerebral haemorrhage or retinal haemorrhage
9. Pregnancy or breastfeeding
10. Impaired renal function

Date of first enrolment

01/12/2010

Date of final enrolment

01/02/2012

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre
The Light Laboratories
Leeds
United Kingdom
LS2 9DA

Sponsor information

Organisation
University of Leeds (UK)

ROR
<https://ror.org/024mrx33>

Funder(s)

Funder type
Charity

Funder Name
Heart Research UK (UK)

Alternative Name(s)
HRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		26/07/2020	19/05/2022	No	No
HRA research summary			28/06/2023	No	No